Gaur, Aditya H <br/><br/>
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial.  [electronic resource] 

 -  The lancet. HIV  12 2016 
 - e561-e568 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>2352-3018 
<br/><br/><label>Standard No.: </label>10.1016/S2352-3018(16)30121-7  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adenine--administration & dosage<br/>Adolescent<br/>Alanine<br/>Anti-HIV Agents--administration & dosage<br/>Area Under Curve<br/>CD4 Lymphocyte Count<br/>Child<br/>Cobicistat--administration & dosage<br/>Drug Therapy, Combination<br/>Emtricitabine--administration & dosage<br/>Female<br/>HIV Infections--drug therapy<br/>HIV-1--genetics<br/>Humans<br/>Lost to Follow-Up<br/>Male<br/>Quinolones--administration & dosage<br/>RNA, Viral--blood<br/>South Africa--epidemiology<br/>Tablets<br/>Tenofovir--analogs & derivatives<br/>Thailand--epidemiology<br/>Uganda--epidemiology<br/>United States--epidemiology<br/>Viral Load